Trimetazidine is banned in sports because it changes how cells produce energy in a way that could give athletes an unfair advantage. The World Anti-Doping Agency (WADA) added it to its Prohibited List on January 1, 2014, classifying it as an S4.4.4 substance under the category of hormone and metabolic modulators. It works by shifting the body’s fuel source from fat to glucose, which produces energy more efficiently under physical stress.
What Trimetazidine Does in the Body
Trimetazidine was originally developed in 1969 as a heart medication. It treats stable angina, the chest pain that occurs when the heart muscle doesn’t get enough oxygen-rich blood. It’s approved in France and many other countries but has never been approved by the FDA in the United States. Patients typically take it as a 35 mg pill twice daily or an 80 mg modified-release pill once daily.
The drug works by blocking an enzyme involved in burning fatty acids for energy. When that pathway is suppressed, cells pivot to burning glucose instead. This matters because glucose produces energy using less oxygen than fat does. For a heart struggling with reduced blood flow, that’s a meaningful advantage: the same amount of oxygen yields more usable energy. The drug also preserves mitochondrial function, the energy-producing machinery inside cells.
Why It Matters for Athletic Performance
The same metabolic shift that helps angina patients is what concerns anti-doping authorities. When muscles burn glucose more efficiently per unit of oxygen, an athlete could theoretically sustain higher output before hitting the wall of oxygen debt. Research in animal models has shown that trimetazidine improves exercise capacity, preserves skeletal muscle performance, and increases the proportion of slow-twitch muscle fibers, the type used for endurance. In one study, mice treated with trimetazidine showed lower blood lactic acid levels during exercise, greater glycogen use, and better mitochondrial function compared to untreated animals.
The drug also appears to protect muscles from damage. Research published in the Journal of Cachexia, Sarcopenia and Muscle found that trimetazidine restored exercise capacity in mice whose muscles had been injured by statin medications. It improved the activity of a key component of the mitochondrial energy chain and reduced oxidative stress, the cellular damage that accumulates during intense physical effort. For an athlete, less muscle damage and faster recovery between training sessions could translate to a real competitive edge.
How WADA Justified the Ban
WADA can prohibit any substance that meets at least two of three criteria: it has the potential to enhance performance, it poses a health risk to athletes, or it violates the spirit of sport. Trimetazidine checks all three boxes. Its metabolic effects offer a plausible performance benefit, its side effects include serious neurological symptoms, and using a heart medication without a cardiac condition to gain an edge clearly falls outside fair competition.
The classification under S4 (hormone and metabolic modulators) rather than as a stimulant reflects how the drug works. It doesn’t amp up the nervous system the way caffeine or amphetamines do. Instead, it quietly reprograms cellular metabolism, making energy production more efficient at a fundamental level. That metabolic manipulation is exactly what the S4 category was designed to catch.
Health Risks for Athletes
Trimetazidine carries a concerning side effect profile, particularly involving the nervous system. A systematic review published in Frontiers in Neurology documented a growing number of cases where the drug caused parkinsonism: symptoms resembling Parkinson’s disease, including slowness of movement, muscle rigidity, postural instability, and difficulty walking. These symptoms typically appeared after months of use at standard therapeutic doses of 60 to 80 mg per day, though onset ranged from as little as one month to as long as 20 years.
The good news in the clinical literature is that these symptoms were usually reversible. In most reported cases, patients recovered fully or improved significantly after stopping the drug, with symptom resolution taking anywhere from a few weeks to several months. The movement problems tended to be mild and symmetrical, distinguishing them from typical Parkinson’s disease, which usually starts on one side of the body and is more severe. Most cases occurred in patients over 65, so the risk to younger athletes is less well documented, but the neurological potential is enough to raise red flags.
Detection and Testing
Anti-doping labs can detect trimetazidine in dried blood spots for up to 60 hours after a single dose. Urine testing extends the detection window further, which is the standard method used in competition testing. A study from Poland examining excretion patterns after oral administration confirmed that the drug and its metabolites are reliably identifiable through routine doping control procedures.
The relatively short detection window compared to some banned substances means an athlete could theoretically time their use to avoid detection, which is one reason out-of-competition testing remains important. WADA’s current classification prohibits trimetazidine at all times, not just during competition, closing this loophole. Any trace found in a sample, regardless of when it was collected, constitutes a violation.
High-Profile Cases
Trimetazidine gained widespread public attention during the 2022 Beijing Winter Olympics when Russian figure skater Kamila Valieva tested positive for the substance. The case highlighted both how obscure the drug is outside of cardiology and how its metabolic effects make it relevant across a wide range of sports, not just endurance events. Figure skating demands explosive power, precise motor control, and the ability to recover quickly between programs, all areas where improved cellular energy efficiency could matter.
The Valieva case also underscored a practical reality: trimetazidine is widely prescribed in Russia and Eastern Europe for heart conditions, making accidental exposure through a family member’s medication at least plausible, though anti-doping rules hold athletes strictly liable regardless of intent. Several other athletes across cycling, boxing, and swimming have also tested positive for the drug since its 2014 ban.